In 2006, a Rise in Ophthalmic Surgeries

The diseases of the eye--cataracts, age-related macular degeneration and presbyopia--are largely degenerative conditions that are the result of aging and are every bit as prevalent as cardiovascular disease and the aches and pains that accompany joint degeneration. In 2006, ophthalmic surgical procedures represented approximately 23.2% of all surgeries performed in the US, according to "US Surgical Procedure Volumes," a report recently issued by the Medtech Insight division of Windhover Information, and procedure numbers are expected to climb at a compound annual growth rate of 4.2% through 2014.

The diseases of the eye—cataracts, age-related macular degeneration, presbyopia—are largely degenerative conditions that are the result of aging and are every bit as prevalent as cardiovascular disease and the aches and pains that accompany joint degeneration. In 2006, ophthalmic surgical procedures represented approximately 23.2% of all surgeries performed in the US, and procedure numbers are expected to climb at a compound annual growth rate of 4.2% through 2014, according to US Surgical Procedure Volumes, a report recently issued by the Medtech Insight division of Windhover Information.

Demographics will fuel growth in the number of eye surgeries for conditions such as cataracts—20 million patients were treated in...

More from Archive

More from Scrip

Four Chinese Firms Snag Global First-In-Class Approvals In China

 

Four Chinese companies have won approvals in China, the first anywhere, for novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A.

AbbVie Licenses IGI’s ISB 2001 In Second Myeloma Trispecific Deal For 2025

 

IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.

Merck & Co. Remains In The BD Game After Verona Takeout

 

CEO Rob Davis said the company is in pursuit of more deals as it looks to close the revenue gap looming from the loss of Keytruda in 2028.